

Henry F Chambers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/151754/publications.pdf>

Version: 2024-02-01

92
papers

12,812
citations

109321

35
h-index

53230

85
g-index

95
all docs

95
docs citations

95
times ranked

12411
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children. <i>Clinical Infectious Diseases</i> , 2011, 52, e18-e55.	5.8	2,673
2	Waves of resistance: <i>Staphylococcus aureus</i> in the antibiotic era. <i>Nature Reviews Microbiology</i> , 2009, 7, 629-641.	28.6	2,049
3	Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, e10-e52.	5.8	1,711
4	Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i> . <i>New England Journal of Medicine</i> , 2006, 355, 653-665.	27.0	1,347
5	Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, 147-159.	5.8	1,156
6	Reemergence of antibiotic-resistant <i>Staphylococcus aureus</i> in the genomics era. <i>Journal of Clinical Investigation</i> , 2009, 119, 2464-2474.	8.2	410
7	Daptomycin: Another Novel Agent for Treating Infections Due to Drug-Resistant Gram-Positive Pathogens. <i>Clinical Infectious Diseases</i> , 2004, 38, 994-1000.	5.8	319
8	Can Ceftazidime-Avibactam and Aztreonam Overcome β -Lactam Resistance Conferred by Metallo- β -Lactamases in Enterobacteriaceae?. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	217
9	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 731-741.	9.1	174
10	Clindamycin versus Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Infections. <i>New England Journal of Medicine</i> , 2015, 372, 1093-1103.	27.0	166
11	A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. <i>New England Journal of Medicine</i> , 2017, 376, 2545-2555.	27.0	156
12	Clinical outcomes and bacterial characteristics of carbapenem-resistant <i>Klebsiella pneumoniae</i> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 401-412.	9.1	122
13	Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Infection and Chemotherapy</i> , 2016, 48, 267.	2.3	120
14	The Emperor's New Clothes: Prospective Observational Evaluation of the Association Between Initial Vancomycin Exposure and Failure Rates Among Adult Hospitalized Patients With Methicillin-resistant <i>Staphylococcus aureus</i> Bloodstream Infections (PROVIDE). <i>Clinical Infectious Diseases</i> , 2020, 70, 1536-1545.	5.8	106
15	Imipenem for Treatment of Tuberculosis in Mice and Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2816-2821.	3.2	105
16	Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 884-888.	3.2	94
17	A <i>mecA</i> -Negative Strain of Methicillin-Resistant <i>Staphylococcus aureus</i> with High-Level β -Lactam Resistance Contains Mutations in Three Genes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4900-4902.	3.2	90
18	<i>Staphylococcus aureus</i> Bacteremia at 5 US Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections. <i>Clinical Infectious Diseases</i> , 2014, 59, 798-807.	5.8	85

#	ARTICLE	IF	CITATIONS
19	Native-Valve Infective Endocarditis. <i>New England Journal of Medicine</i> , 2020, 383, 567-576.	27.0	85
20	USA300 and USA500 Clonal Lineages of <i>Staphylococcus aureus</i> Do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the <i>cap5</i> Locus. <i>MBio</i> , 2015, 6, .	4.1	82
21	Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 14-21.	4.7	71
22	MIG-mediated protection against necrotizing pneumonia caused by MRSA. <i>Science Translational Medicine</i> , 2016, 8, 357ra124.	12.4	70
23	Ceftobiprole- and Ceftaroline-Resistant Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2960-2963.	3.2	69
24	Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. <i>JAMA Pediatrics</i> , 2022, 176, 253.	6.2	66
25	Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e296-e301.	9.1	57
26	Endocarditis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> in Rabbits: Expression of Resistance to β -Lactam Antibiotics in Vivo and in Vitro. <i>Journal of Infectious Diseases</i> , 1984, 149, 894-903.	4.0	55
27	Whole-Genome Sequencing of Methicillin-Resistant <i>Staphylococcus aureus</i> Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. <i>PLoS ONE</i> , 2016, 11, e0149541.	2.5	53
28	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. <i>Clinical Infectious Diseases</i> , 2016, 62, 181-189.	5.8	52
29	High-Level Resistance of <i>Staphylococcus aureus</i> to β -Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	44
30	Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in <i>Staphylococcus aureus</i> . <i>Journal of Biological Chemistry</i> , 2018, 293, 19854-19865.	3.4	44
31	Clinical Practice Variation Among Adult Infectious Disease Physicians in the Management of <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2019, 69, 530-533.	5.8	44
32	Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis. <i>JAMA Internal Medicine</i> , 2020, 180, 769.	5.1	44
33	Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx232.	0.9	42
34	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2622-2632.	3.0	39
35	Considerations for Clinical Trials of <i>Staphylococcus aureus</i> Bloodstream Infection in Adults. <i>Clinical Infectious Diseases</i> , 2019, 68, 865-872.	5.8	38
36	Solving staphylococcal resistance to β -lactams. <i>Trends in Microbiology</i> , 2003, 11, 145-148.	7.7	37

#	ARTICLE	IF	CITATIONS
37	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against <i>Pseudomonas aeruginosa</i> : PRIMERS IV. <i>Clinical Infectious Diseases</i> , 2019, 68, 1823-1830.	5.8	37
38	A Prognostic Model of Persistent Bacteremia and Mortality in Complicated <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Clinical Infectious Diseases</i> , 2019, 68, 1502-1511.	5.8	36
39	Ampicillin, Sulbactam, and Rifampin Combination Treatment of Experimental Methicillin-Resistant <i>Staphylococcus aureus</i> Endocarditis in Rabbits. <i>Journal of Infectious Diseases</i> , 1995, 171, 897-902.	4.0	34
40	PBP4: A New Perspective on <i>Staphylococcus aureus</i> β -Lactam Resistance. <i>Microorganisms</i> , 2018, 6, 57.	3.6	34
41	Treatment of Infection and Colonization Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 1991, 12, 29-35.	1.8	33
42	Efficacy of Levofloxacin for Experimental Aortic-Valve Endocarditis in Rabbits Infected with Viridans Group <i>Streptococcus</i> or <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2742-2746.	3.2	33
43	PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3934-3941.	3.2	32
44	PBP4 Mediates β -Lactam Resistance by Altered Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	30
45	Bicarbonate Resensitization of Methicillin-Resistant <i>Staphylococcus aureus</i> to β -Lactam Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	27
46	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against <i>Acinetobacter</i> spp. in PRIMERS III. <i>Journal of Clinical Microbiology</i> , 2017, 55, 134-144.	3.9	26
47	Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant <i>Staphylococcus aureus</i> Causing Infective Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
48	Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
49	Antimicrobial Stewardship Approaches in the Intensive Care Unit. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 513-534.	5.1	24
50	Antibacterial Resistance Leadership Group: Open for Business. <i>Clinical Infectious Diseases</i> , 2014, 58, 1571-1576.	5.8	22
51	Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections. <i>New England Journal of Medicine</i> , 2014, 370, 2238-2239.	27.0	22
52	Trends in prevalence of extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 118.	4.1	22
53	Comparative Efficacies of Tedizolid Phosphate, Vancomycin, and Daptomycin in a Rabbit Model of Methicillin-Resistant <i>Staphylococcus aureus</i> Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3252-3256.	3.2	21
54	Skin and Soft Tissue Infections in Persons Who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 169-181.	5.1	21

#	ARTICLE	IF	CITATIONS
55	Omadacycline – The Newest Tetracycline. <i>New England Journal of Medicine</i> , 2019, 380, 588-589.	27.0	20
56	Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5276-5284.	3.2	19
57	PBP4 activity and its overexpression are necessary for PBP4-mediated high-level β -lactam resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1177-1180.	3.0	19
58	Accessory Genomes Drive Independent Spread of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Clonal Groups 258 and 307 in Houston, TX. <i>MBio</i> , 2022, 13, e0049722.	4.1	17
59	Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate (NaHCO_3) Responsiveness and β -Lactam Sensitization in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
60	Daptomycin- β -Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant <i>Staphylococcus aureus</i> Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3976-3979.	3.2	11
61	Patient-Directed Discharges Among Persons Who Use Drugs Hospitalized with Invasive <i>Staphylococcus aureus</i> Infections: Opportunities for Improvement. <i>American Journal of Medicine</i> , 2022, 135, 91-96.	1.5	11
62	Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for <i>Staphylococcus aureus</i> Bacteremia?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	9
63	Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	9
64	Analytical Evaluation of the Abbott RealTime CT/NG Assay for Detection of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in Rectal and Pharyngeal Swabs. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 811-816.	2.8	8
65	Loss of GdpP Function in <i>Staphylococcus aureus</i> Leads to β -Lactam Tolerance and Enhanced Evolution of β -Lactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0143121.	3.2	8
66	Efficacy of cefoperazone in combination with sulbactam in experimental <i>Staphylococcus aureus</i> endocarditis in rabbits. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 453-458.	3.0	7
67	Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Biological Chemistry</i> , 2020, 295, 10870-10884.	3.4	7
68	Antibacterial Resistance Leadership Group 2.0: Back to Business. <i>Clinical Infectious Diseases</i> , 2021, 73, 730-739.	5.8	7
69	A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: β -Lactam Sensitization among Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA). <i>Antibiotics</i> , 2021, 10, 1089.	3.7	7
70	Impact of Bicarbonate- β -Lactam Exposures on Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Gene Expression in Bicarbonate- β -Lactam-Responsive vs. Non-Responsive Strains. <i>Genes</i> , 2021, 12, 1650.	2.4	7
71	Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab651.	0.9	6
72	Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. <i>Journal of Infectious Diseases</i> , 2022, 226, 1109-1119.	4.0	6

#	ARTICLE	IF	CITATIONS
73	Prosthetic Valve Endocarditis Diagnosis and Management—New Paradigm Shift Narratives. <i>Clinical Infectious Diseases</i> , 2021, 72, 1687-1692.	5.8	5
74	Impacts of NaHCO ₃ on β -Lactam Binding to PBP2a Protein Variants Associated with the NaHCO ₃ -Responsive versus NaHCO ₃ -Non-Responsive Phenotypes. <i>Antibiotics</i> , 2022, 11, 462.	3.7	4
75	The NaHCO ₃ -Responsive Phenotype in Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Is Influenced by <i>mecA</i> Genotype. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0025222.	3.2	3
76	Rifabutin to the Rescue?. <i>Journal of Infectious Diseases</i> , 2020, 222, 1422-1424.	4.0	2
77	Skin and Soft Tissue Infections. <i>Infectious Disease Clinics of North America</i> , 2021, 35, xiii-xiv.	5.1	2
78	Can Rapid Molecular Diagnostics Assist in the Choice of β -Lactam Antibiotics? An Analysis of Data from PRIMERS-II of the Antibiotic Resistance Leadership Group (ARLG). <i>Open Forum Infectious Diseases</i> , 2014, 1, S28-S28.	0.9	1
79	Probability of Eradication Using Vancomycin Alone or in Combination for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7617-7617.	3.2	1
80	Reply to Lesho and Clifford. <i>Clinical Infectious Diseases</i> , 2016, 63, 571-572.	5.8	1
81	2276. Clinical Epidemiology of the Carbapenem-Resistant Enterobacteriaceae (CRE) Epidemic in Colombia: A Multicenter Prospective Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S779-S779.	0.9	1
82	Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit. <i>JAMA Internal Medicine</i> , 2020, 180, 138.	5.1	1
83	Differential Trends in Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis. <i>Microbial Drug Resistance</i> , 2021, 27, 154-161.	2.0	1
84	175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). <i>Open Forum Infectious Diseases</i> , 2020, 7, S216-S216.	0.9	1
85	Endogenous or Exogenous Origin of Platelet-Activating Factor in Cerebrospinal Fluid of Children with Bacterial Meningitis-Reply. <i>Journal of Infectious Diseases</i> , 1991, 163, 1166-1166.	4.0	0
86	Merle A. Sande: 1939–2007. <i>Clinical Infectious Diseases</i> , 2008, 46, 1743-1744.	5.8	0
87	Reply to Cataldo et al. <i>Clinical Infectious Diseases</i> , 2011, 53, 310-310.	5.8	0
88	724 Vancomycin Minimum Inhibitory Concentration Does Not Predict Death, Recurrence or Readmission in Patients with <i>Staphylococcus aureus</i> Bacteremia in a Safety-Net Hospital. <i>Open Forum Infectious Diseases</i> , 2014, 1, S204-S204.	0.9	0
89	Epidemiology of community-associated methicillin-resistant <i>Staphylococcus aureus</i> in San Francisco children. <i>Journal of Pediatric Infectious Diseases</i> , 2015, 04, 247-259.	0.2	0
90	607. Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate [NaHCO ₃]-Responsivity and β -Lactam Sensitization among Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA). <i>Open Forum Infectious Diseases</i> , 2019, 6, S284-S284.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Community-Onset Oxacillin-Resistant <i>Staphylococcus aureus</i> Infection. , 0, , 85-93.		0
92	39. Comparative One-year Outcomes of Invasive <i>Staphylococcus Aureus</i> infections Among Persons with and Without Drug Use in an Urban West Coast Cohort. <i>Open Forum Infectious Diseases</i> , 2020, 7, S20-S21.	0.9	0